MedTrace Logo

Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer

NCT01875380 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2017-08-01

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of single-agent regorafenib in the first line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC)

Conditions

Interventions

DRUG

Regorafenib

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    lead OTHER

Principal Investigators

  • Alfredo Carrato, MD-PhD · Ramon y Cajal University Hospital

  • Enrique Grande, MD · Ramon y Cajal University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01875380 on ClinicalTrials.gov